scope and timelines, the ability of Optimer and its third party contractors to manufacture and supply sufficient quantities of DIFICID in accordance with Good Manufacturing Practices to meet demand, whether healthcare professionals will prescribe DIFICID, whether DIFICID will receive reimbursement coverage from healthcare payors and government agencies, the extent to which DIFICID will be accepted on hospital formularies, Optimer's ability to successfully manage a sales and marketing organization and other risks detailed in Optimer's filings with the Securities and Exchange Commission.
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005Optimer Pharmaceuticals, Inc.Consolidated Statements of Operations(unaudited) Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2011201020112010Revenues:Licensing
- $69,165,000 $
- Research grants
33,294357,436144,933654,873 Total revenues
33,294357,43669,309,933654,873Cost and expenses: Cost of licensing
--4,273,532-Research and development
6,974,322656,46410,407,915925,058General and administrative
7,506,5253,686,44215,786,7076,075,154Total operating expenses
25,051,48310,762,15749,509,29924,781,042Income (loss) from operations
(25,018,189)(10,404,721)19,800,634(24,126,169)Interest income and other, net
95,86053,719119,10278,497Consolidated net income (loss)
$ (24,922,329)$ (10,351,002)$19,919,736$(24,047,672)Net loss attributable to noncontrolling interest
683,483290,105974,288491,020Net income (loss) attributable to Optimer Pharmaceuticals, Inc.
$ (24,238,846)$ (10,060,897)$20,894,024$(23,556,652)Net income (loss) per share - basic
Page: 1 2 3 4 5 Related medicine technology :1
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older2
. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)3
. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference4
. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results5
. Optimer Pharmaceuticals Expands Senior Management Team6
. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences7
. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States8
. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)9
. Trading Halted Today in Optimer Pharmaceuticals Stock10
. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients11
. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality